STRO – sutro biopharma, inc. (US:NASDAQ)
Stock Stats
News
Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference 
Sutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established first-in-class cell-free capabilities at commercial scale
Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless [Seeking Alpha]
Sutro Biopharma, Inc. (NASDAQ: STRO) had its price target lowered by analysts at Wells Fargo & Company from $5.00 to $4.00. They now have an "equal weight" rating on the stock.
Sutro Biopharma, Inc. (NASDAQ: STRO) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $17.00 price target on the stock.
Form 8-K SUTRO BIOPHARMA, INC. For: Dec 10
Form 4 SUTRO BIOPHARMA, INC. For: Dec 01 Filed by: Chung Jane
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.